Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis

Journal of Clinical Virology

Volumn 57, Issue 3, 2013, Pages 209-214

  Dong, Hua Jie ^a   Ni, Ling Na ^a   Sheng, Gui Feng ^a   Song, Hong Lei ^a   Xu, Jian Zhong ^a   Ling, Yang ^a  

^a China   (China)

Author keywords

Hepatitis B virus; Meta analysis; Non Hodgkin lymphoma; Reactivation; Rituximab

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; CANCER PATIENT; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS REACTIVATION; DRUG EFFECTS; LYMPHOMA, NON-HODGKIN; RISK ASSESSMENT; VIRUS ACTIVATION; DRUG EFFECT; REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HEPATITIS B VIRUS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, NON-HODGKIN; RISK ASSESSMENT; VIRUS ACTIVATION;

EID: 84891429810     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.03.010     Document Type: Article

References (31)

1. Dienstag J.L. Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
2. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011, 32:405-415.
3. Aksoy S., Harputluoglu H., Kilickap S., Dede D.S., Dizdar O., Altundag K., et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007, 48:1307-1312.
4. Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
5. Loomba R., Liang T.J. Novel approaches to new therapies for hepatitis B virus infection. Antivir ther 2006, 11:1-15.
6. Ziakas P.D., Karsaliakos P., Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009, 94:998-1005.
7. European Association For The Study of The L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
8. Sugauchi F., Tanaka Y., Kusumoto S., Matsuura K., Sugiyama M., Kurbanov F., et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011, 83:412-418.
9. Fukushima N., Mizuta T., Tanaka M., Yokoo M., Ide M., Hisatomi T., et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009, 20:2013-2017.
10. Hui C.K., Cheung W.W., Zhang H.Y., Au W.Y., Yueng Y.H., Leung A.Y., et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
11. Ji D., Cao J., Hong X., Li J., Wang J., Chen F., et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010, 85:243-250.
12. Koo Y.X., Tan D.S., Tan I.B., Tao M., Chow W.C., Lim S.T. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010, 116:115-121.
13. Luo J.Z., Fan Y.Q., Luo Y.M., Su R., Wu Xl. Clinical observation of the effect of prophylactic lamivudine for hepatitis B reactivation in lymphoma. Clin Med China 2010, 26:1255-1256.
14. Targhetta C., Cabras M.G., Mamusa A.M., Mascia G., Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008, 93:951-952.
15. Tsutsumi Y., Shigematsu A., Hashino S., Tanaka J., Chiba K., Masauzi N., et al. Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido. Ann Hematol 2009, 88:375-377.
16. Wang F., Xu R.H., Luo H.Y., Zhang D.S., Jiang W.Q., Huang H.Q., et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008, 8:115.
17. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
18. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
19. Evens A.M., Jovanovic B.D., Su Y.C., Raisch D.W., Ganger D., Belknap S.M., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011, 22:1170-1180.
20. Lee I.C., Huang Y.H., Chu C.J., Lee P.C., Lin H.C., Lee S.D. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc 2010, 73:156-160.
21. Yeo W., Chan P.K., Zhong S., Ho W.M., Steinberg J.L., Tam J.S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299-307.
22. Garcia-Rodriguez M.J., Canales M.A., Hernandez-Maraver D., Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?. Am J Hematol 2008, 83:673-675.
23. He Y.F., Li Y.H., Wang F.H., Jiang W.Q., Xu R.H., Sun X.F., et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008, 87:481-485.
24. Yang S.H., Kuo S.H. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008, 87:325-327.
25. Dai M.S., Chao T.Y., Kao W.Y., Shyu R.Y., Liu T.M. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004, 83:769-774.
26. Davis J. Preventing hepatitis B virus reactivation following immunosuppressive therapy. Intern Med J 2008, 38:617. author reply 17-8.
27. Law J.K., Ali J.A., Harrigan P.R., Sherlock C.H., Savage K.J., Yoshida E.M. Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol 2006, 81:969-972.
28. Marino D., Boso C., Crivellari G., Mazzarotto R., Stragliotto S., Farinati F., et al. Fatal HBV-related liver failure during lamivudine therapy in a patient with non-Hodgkin's lymphoma. Tumori 2008, 94:748-749.
29. Aomatsu T., Komatsu H., Yoden A., Hosomi A., Miyazaki H., Sogo T., et al. Fulminant hepatitis B and acute hepatitis B due to intrafamilial transmission of HBV after chemotherapy for non-Hodgkin's lymphoma in an HBV carrier. Eur J Pediatr 2010, 169:167-171.
30. Schnepf N., Sellier P., Bendenoun M., Zini J.M., Sanson-le Pors M.J., Mazeron M.C. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol 2007, 39:48-50.
31. Liaw Y.F., Kao J.H., Piratvisuth T., Chan H., Chien R.N., Liu C.J., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.